Company: FTII
Filing Date: 2025-01-28
Form Type: 10-Q
Source: 0001493152-25-004006
Chunk: 145

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-01-28
Form: 10-Q
Item: Part I, Item 8
Chunk 145
---

properly exercised their right to redeem their shares for cash at a redemption price of approximately $11.01 per share as disclosed in
the Proxy Statement. The Company is working on calculating the actual redemption price for the Third Extension and intends to disclose it by filing a Current Report on Form 8-K as soon as it is available.

On
November 20, 2024, the Company caused to be deposited $37,744 into the Company’s Trust account, allowing the Company to extend
the period of time it has to consummate its initial Business Combination from November18, 2024 to December 18, 2024. On December 18,
2024, the Company caused to be deposited $37,744 into the Company’s Trust account, allowing the Company to extend the period
of time it has to consummate its initial Business Combination from December 18, 2024 to January 18, 2025. On January 18, 2025, the Company
caused to be deposited $37,744 into the Company’s Trust account, allowing the Company to extend the period of time it has to
consummate its initial Business Combination from January 18, 2025 to February 18, 2025.

As
of September 30, 2024, there was $3,300,000 outstanding under the Extension Loans from the Sponsor. As of the date hereof, there is
approximately $3,400,000 outstanding under the Extension Loans from the Sponsor.

5

Recent
Developments

Business
Combination

On
September 16, 2024, the Company, entered into a Merger Agreement”, by and among the Company, Longevity, LBI Merger Sub, Inc., and
Bradford A. Zakes, solely in the capacity as seller representative.

Pursuant
to the Merger Agreement, the parties thereto will enter into the Transactions, pursuant to which, among other things, immediately following
the consummation of the acquisitions by Longevity of each of Cerevast Medical, Inc. and Aegeria Soft Tissue LLC, Longevity will merge
with and into LBI Merger Sub, with Longevity as the surviving entity and becoming a wholly-owned subsidiary of the Company. At the closing
of the Transactions (the “Closing”), the Company is expected to change its name to “Longevity Biomedical, Inc.”
and the Company’s common stock is expected to list on the NASDAQ Capital Market